The Use of Ivermectin in the Treatment of COVID-19.
作者信息
Shukla Ajay Kumar, Misra Saurav
机构信息
Department of Pharmacology, AIIMS Bhopal, Bhopal, India.
Department of Pharmacology, Kalpana Chawla Government Medical College, Karnal, India.
出版信息
J Gen Intern Med. 2023 May;38(6):1554. doi: 10.1007/s11606-023-08104-8. Epub 2023 Feb 28.
Abstract
摘要
相似文献
1
The Use of Ivermectin in the Treatment of COVID-19.伊维菌素在治疗新冠病毒病中的应用
J Gen Intern Med. 2023 May;38(6):1554. doi: 10.1007/s11606-023-08104-8. Epub 2023 Feb 28.
2
Unethical studies of ivermectin for covid-19.关于伊维菌素用于治疗新冠病毒的不道德研究。
BMJ. 2022 Apr 14;377:o917. doi: 10.1136/bmj.o917.
3
Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis.伊维菌素作为 COVID-19 附加治疗的治疗潜力：系统评价和荟萃分析。
J Pharm Pharm Sci. 2020;23:462-469. doi: 10.18433/jpps31457.
4
Role of ivermectin in patients hospitalized with COVID-19: a systematic review of literature.伊维菌素在 COVID-19 住院患者中的作用：文献系统评价。
Adv Respir Med. 2021;89(4):413-418. doi: 10.5603/ARM.a2021.0088.
5
Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients.评估在重症 COVID-19 患者的治疗中添加伊维菌素的有效性和安全性。
BMC Infect Dis. 2021 May 4;21(1):411. doi: 10.1186/s12879-021-06104-9.
6
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial.伊维菌素预防 COVID-19 患者住院（IVERCOR-COVID19）：一项随机、双盲、安慰剂对照试验。
BMC Infect Dis. 2021 Jul 2;21(1):635. doi: 10.1186/s12879-021-06348-5.
7
Intensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for COVID-19 in Health Care Workers From Tucuman, Argentina.在阿根廷图库曼的医护人员中，使用伊维菌素和iota-卡拉胶进行强化治疗作为COVID-19暴露前预防措施。
Am J Ther. 2021 Aug 16;28(5):e601-e604. doi: 10.1097/MJT.0000000000001433.
8
Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19.伊维菌素治疗可能改善新冠病毒肺炎患者的预后。
Arch Bronconeumol (Engl Ed). 2020 Dec;56(12):828-830. doi: 10.1016/j.arbr.2020.08.011. Epub 2020 Dec 14.
9
Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.伊维菌素：一种具有抗 COVID-19 预期抗病毒活性的获奖药物。
J Control Release. 2021 Jan 10;329:758-761. doi: 10.1016/j.jconrel.2020.10.009. Epub 2020 Oct 7.
10
Considerations on the Article "Antiviral and Anti-Inflammatory Properties of Ivermectin and its Potential Use in COVID-19".关于《伊维菌素的抗病毒和抗炎特性及其在COVID-19中的潜在用途》一文的思考
Arch Bronconeumol (Engl Ed). 2020 Dec;56(12):832. doi: 10.1016/j.arbres.2020.08.012. Epub 2020 Sep 16.
引用本文的文献
1
MoMo30 Binds to SARS-CoV-2 Spike Variants and Blocks Infection by SARS-CoV-2 Pseudovirus.莫莫 30 结合 SARS-CoV-2 刺突变异株并阻断 SARS-CoV-2 假病毒感染。
Viruses. 2024 Sep 7;16(9):1433. doi: 10.3390/v16091433.
2
Lessons Learned from Ivermectin.从伊维菌素中吸取的教训。
J Gen Intern Med. 2023 May;38(6):1555. doi: 10.1007/s11606-023-08105-7. Epub 2023 Feb 27.
本文引用的文献
1
Incidence of and Ivermectin Prescription Trends for COVID-19 in Japan.日本新冠病毒病的伊维菌素处方趋势及发病率
J Gen Intern Med. 2023 Mar;38(4):1078-1080. doi: 10.1007/s11606-022-07877-8. Epub 2022 Nov 2.
2
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.二甲双胍、伊维菌素和氟伏沙明治疗 COVID-19 的随机试验。
N Engl J Med. 2022 Aug 18;387(7):599-610. doi: 10.1056/NEJMoa2201662.
3
Antiviral Effects of Ivermectin in COVID-19- Clinically Plausible?伊维菌素对新冠病毒的抗病毒作用——从临床角度看是否合理？
Int J Infect Dis. 2021 Aug;109:91. doi: 10.1016/j.ijid.2021.06.048. Epub 2021 Jun 24.
4
Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial.伊维菌素对轻症 COVID-19 成人症状缓解时间的影响：一项随机临床试验。
JAMA. 2021 Apr 13;325(14):1426-1435. doi: 10.1001/jama.2021.3071.
Zotero 插件